Rigel Pharmaceuticals RIGL Payment of cost share to collaboration partner
Discontinued — last reported Q4 '25
Payment of cost share to collaboration partner at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept rigl:PaymentOfCostShareToCollaborationPartner.
The official record: Rigel Pharmaceuticals’s 10-K, filed March 3, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's payment of cost share to collaboration partner.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rigel Pharmaceuticals's payment of cost share to collaboration partner?
- Rigel Pharmaceuticals (RIGL) reported payment of cost share to collaboration partner of $0 in Q4 2025.
- What is the long-term trend for Rigel Pharmaceuticals's payment of cost share to collaboration partner?
- Over 2 years (2022 to 2025), Rigel Pharmaceuticals's payment of cost share to collaboration partner has grown at a -100.0% compound annual growth rate (CAGR), from $15.12M to $0.
- What does payment of cost share to collaboration partner mean?
- Represents cash payments made to collaboration partners to satisfy obligations under joint development or commercialization agreements. This metric highlights the cash impact of shared-cost structures in strategic alliances. It is essential for understanding the net cash burden of maintaining collaborative drug development pipelines.